Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Zhejiang Hisun Pharmaceutical Co., Ltd.
483
•Zhejiang Hisun Pharmaceutical Co., Ltd.•January 19, 2017

Zhejiang Hisun Pharmaceutical Co., Ltd. – FDA 483, Jan 19, 2017

Record Details

During an inspection from January 16-19, 2017, the FDA issued a Form 483 to Zhejiang Hisun Pharmaceutical Co., Ltd., an Active Pharmaceutical Ingredient manufacturer in Taizhou City, China. The inspection revealed significant concerns primarily related to data integrity and stability study deficiencies. A key observation highlighted the firm's failure to adhere to Quality Control laboratory control procedures. Despite having received a previous FDA Warning Letter in December 2015 regarding analytical data integrity and submitting an investigation report claiming no similar issues, the current inspection identified numerous unaddressed data integrity breaches. These included the deletion and overwriting of analytical data, and the performance of analyses with audit trails disabled. The FDA's limited review found approximately 23 such instances, with only three having been reported by the company in their earlier investigation. Additionally, the inspection found that labeled storage conditions for an API batch were not justified by stability studies. An Out-of-Specification result for impurities was confirmed, and no supporting stability data existed for the stated expiration date. The firm also transferred samples to non-representative storage conditions after a stability failure. The company is expected to implement comprehensive corrective actions to resolve these serious observations, ensuring compliance with regulatory standards for data integrity and product stability.

Company
Zhejiang Hisun Pharmaceutical Co., Ltd.
Inspection date
January 19, 2017
Office
Office of Scientific Investigations
People
  • Lindsey M. Schwaigerjohann
  • Peter E. Baker (President)
View Company Profile

ID · 5bce805f-5cef-44fe-bc93-6f7b46060574

Violation Codes5
21 U.S.C. 324(a)(4)FD&C Act 905(j)FD&C Act 801(a)(3)21 CFR 331(c)21 CFR 483

Full citation text and observation details available on the Dashboard.

Other documents for Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 483 - 2019-06-07June 7, 2019
  • 483 - 2017-08-11August 11, 2017
  • 483 - 2017-08-07August 7, 2017
  • 483 - 2017-01-16January 16, 2017
  • WARNING_LETTER - 2015-03-07March 7, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Hisun Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.